Morphologic, intraoperative, and histologic risk factors for sinonasal inverted papilloma recurrence. (21st May 2019) - Lee, Jake J.
Abstract : Objective: Sinonasal inverted papillomas (IP) are benign neoplasms with a propensity for local recurrence. Many risk factors are reported, with little consistency between studies. This study aimed to comprehensively assess for demographic, imaging, histopathologic, and intraoperative risk factors for recurrence. Methods: We performed a single‐center retrospective cohort study of patients with pathologically diagnosed IP without malignancy who underwent surgical resection between 1997 and 2018. Eligible patients were identified through a database maintained by the Department of Pathology. Logistic regression identified variables associated with recurrence, and conjunctive consolidation was performed to create a predictive model. Results: Of 76 subjects, 37% ( n = 28) had recurrence. Median follow‐up and time to recurrence were 2.9 (range 0.5–21.1) and 1.7 (range 0.2–13.0) years, respectively. Confirmed negative margins on histology were protective (odds ratio [OR] 0.25, 95% confidence interval [CI] 0.08–0.85). Frontal sinus involvement (adjusted odds ratio [aOR] 5.83, 95% CI 1.20–28.37), incomplete resection (aOR 9.67, 95% CI 2.24–41.72), and presence of dysplasia (aOR 4.38, 95% CI 1.01–19.10) were significantly associated with recurrence on multivariable analysis. A three‐level composite recurrence risk staging system was created by consolidating the above three variables. The recurrence risks of composite stage I, II, and III disease were 20%, 38%, and 100%, respectively. No demographic, imaging, staging, or surgical approach variables were associated with recurrence. Conclusion: Frontal sinus involvement, incomplete resection, and dysplasia were significant risk factors for IP recurrence, whereas confirmed negative margins were protective. Creation of a composite staging system using the above variables may allow for risk stratification and a patient‐specific approach to postoperative IP management. Level of Evidence: 3 Laryngoscope, 130:590–596, 2020